PTC postpones IPO, waits for new data

With new clinical data scheduled to arrive in a matter of months, PTC Therapeutics announced that it will postpone a planned IPO. President and Chief Executive Stuart Peltz added that the company is in a strong financial position, with $42 million from a series of upfront payments from development partners and $20 million in grants and research funds.

"With three Phase II studies ongoing in genetic disorders for our most advanced program, PTC124, and with our second most advanced program, PTC299, about to enter Phase 1b clinical development in breast cancer, we are excited about the coming year," said Peltz.

- check out the release
- read the AP report for more information

Related Articles:
PTC files for $86M IPO. Report
Schering-Plough, PTC to collaborate. Report
PTC inks deal with CV. Report

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.